Aytu BioScience (AYTU) AI Stock Analysis

• Market Cap: $15.76M
• Dividend Yield: N/A
• Average Volume (3M): 206.19K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.70
• Revenue Growth: -26.17%
• EPS Growth: N/A
• Country: US
• Employees: 102
• Sector: Healthcare
• Sector Strength: 40
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.20
• Shares Outstanding: 6,170,246
• 10 Day Avg. Volume: 157,434
• 30 Day Avg. Volume: 206,188
• PEG Ratio: 0.15
• Price to Book (P/B): 0.38
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.31
• Enterprise Value/Market Cap: -0.19
• Enterprise Value/Revenue: >-0.01
• Enterprise Value/Gross Profit: -0.06
• Enterprise Value/Ebitda: -0.93
• 1Y Price Target: $9.67
• Price Target Upside: 267.68% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 65 Neutral
• Price Target: $2.50 ▼(-4.94%Downside)

Aytu BioScience's overall score is driven by strong earnings call results and positive corporate events, suggesting future growth potential. However, financial performance challenges and valuation concerns limit the score. Technical analysis indicates current bullish momentum but also overbought conditions.

Positive Factors

Clinical Trials

EXXUA has demonstrated significant improvement in depression symptoms in clinical trials involving more than 5,000 patients, with side effects comparable to placebo.

Market Potential

EXXUA is targeting the $22 billion U.S. prescription MDD market and aims to become an important treatment option for the 21 million Americans affected by MDD.

Revenue Performance

Aytu reported F3Q25 results with total revenue of $18.5M, exceeding the estimate of $13.7M.

Negative Factors

Business Divestment

The decline in total revenue was largely due to the divestment of the lower margin Consumer Health business.

Revenue Decline

ADHD revenue, Aytu’s primary source of prescription revenue, experienced a decline and was below the analyst's estimate.

Aytu BioScience Business Overview & Revenue Model

Company Description

Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.

How the Company Makes Money

Aytu BioScience generates revenue primarily through the sale of its pharmaceutical products. The company's key revenue streams include prescription product sales, over-the-counter product sales, and potentially licensing agreements or partnerships with other pharmaceutical companies. Aytu BioScience may also engage in strategic collaborations to expand its product offerings or market reach, contributing to its earnings. This revenue model relies on strong distribution networks and effective marketing strategies to maximize product accessibility and adoption in target markets.

Aytu BioScience Financial Statement Overview

Summary

Aytu BioScience shows strong gross profit margins but faces challenges in profitability and cash flow generation. The balance sheet is stable with low leverage; however, asset efficiency and cash flow management need improvement.

Income Statement

The income statement reveals fluctuating revenues and profitability challenges. The TTM (Trailing-Twelve-Months) gross profit margin is approximately 68.58%, indicating strong cost management. However, the net profit margin is weak at 2.37%, reflecting ongoing profitability struggles. Revenue decreased significantly in the latest TTM compared to the previous year, impacting the overall financial health.

Balance Sheet

The balance sheet shows a modest debt-to-equity ratio of 0.05, indicating low financial leverage. The equity ratio stands at 28.09%, suggesting a balanced capital structure. However, the return on equity (ROE) is low at 4.70%, highlighting limited profitability relative to shareholder equity. While the company maintains a strong cash position, overall asset efficiency needs improvement.

Cash Flow

The cash flow analysis highlights negative free cash flow, reflecting cash burn and operational challenges. The TTM operating cash flow to net income ratio is negative, indicating difficulties in converting income into cash. The free cash flow to net income ratio is also negative, reinforcing concerns about cash generation capabilities. The company needs to improve cash flow management to support future growth.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	81.00M	107.40M	96.67M	65.63M	27.63M
Gross Profit	54.59M	66.63M	52.28M	29.20M	20.08M
EBITDA	-1.01M	-3.27M	-27.96M	-29.04M	-12.21M
Net Income	-15.84M	-17.05M	-108.78M	-58.29M	-13.62M
Balance Sheet
Total Assets	118.09M	136.46M	137.62M	265.67M	152.84M
Cash, Cash Equivalents and Short-Term Investments	20.01M	22.98M	19.36M	49.65M	48.08M
Total Debt	15.13M	16.36M	18.19M	28.35M	2.01M
Total Liabilities	90.38M	97.11M	93.31M	128.10M	57.82M
Stockholders Equity	27.72M	39.36M	44.31M	137.57M	95.02M
Cash Flow
Free Cash Flow	-1.39M	-5.13M	-28.82M	-28.30M	-28.37M
Operating Cash Flow	-1.39M	-5.13M	-28.82M	-25.96M	-28.37M
Investing Cash Flow	-329.00K	-117.00K	-3.25M	-2.78M	-5.66M
Financing Cash Flow	-1.26M	8.87M	1.53M	30.31M	71.07M

Aytu BioScience Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.63
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AYTU, the sentiment is Positive. The current price of 2.63 is above the 20-day moving average (MA) of 2.30, above the 50-day MA of 2.05, and above the 200-day MA of 1.67, indicating a bullish trend. The MACD of 0.14 indicates Negative momentum. The RSI at 73.17 is Negative, neither overbought nor oversold. The STOCH value of 87.79 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AYTU.

Aytu BioScience Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AYTU	65 Neutral	$15.76M	―	3.29%	―	-26.17%	―
Sector *	52 Neutral	$7.61B	0.04	-62.94%	2.44%	16.14%	0.33%
BFRI	49 Neutral	$9.13M	―	-384.98%	―	14.27%	87.31%
TRIB	47 Neutral	$13.18M	―	77.20%	―	-4.02%	-6.60%
AEMD	38 Underperform	$3.62M	―	-245.88%	―	-100.00%	68.26%
PPBT	35 Underperform	$8.02M	―	-12.35%	―	―	71.57%
NCNA	28 Underperform	$20.23M	―	-205.04%	―	―	35.70%

Aytu BioScience Corporate Events

Aytu BioScience Expands Lending Agreement for EXXUA Launch

On June 20, 2025, Aytu BioPharma, Inc. expanded and extended its lending agreement with Eclipse Business Capital LLC to provide added working capital flexibility in anticipation of the commercial launch of EXXUA™ in late 2025. This agreement includes extending the term loan maturity to June 2029, increasing the principal balance to $13.0 million, and expanding the revolving credit facility by $1.5 million. EXXUA, a novel antidepressant, is expected to enter the over $22 billion U.S. prescription MDD market, addressing significant unmet needs due to its favorable side effect profile demonstrated in clinical trials.

The most recent analyst rating on (AYTU) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Aytu BioScience stock, see the AYTU Stock Forecast page.

Aytu BioPharma Closes $16.6M Stock Offering for EXXUA

On June 9, 2025, Aytu BioPharma announced the closing of an upsized at-the-market public offering of common stock, raising gross proceeds of $16.6 million. The funds are intended to support the commercialization of EXXUA™, a novel FDA-approved treatment for major depressive disorder, which is expected to launch in the fourth quarter of 2025. This strategic move positions Aytu to enter the $22 billion U.S. prescription MDD market, with EXXUA expected to be a significant growth driver due to its unique mechanism and favorable side effect profile.

The most recent analyst rating on (AYTU) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Aytu BioScience stock, see the AYTU Stock Forecast page.

Aytu BioScience Signs Exclusive Agreement for EXXUA

On June 5, 2025, Aytu BioPharma entered an Exclusive Commercialization Agreement with Fabre-Kramer Holdings to commercialize EXXUA™ (gepirone) extended-release tablets in the United States. EXXUA, an FDA-approved treatment for major depressive disorder (MDD), is expected to launch in the fourth quarter of 2025. The agreement involves a series of financial commitments, including upfront and milestone payments, royalties, and a supply price based on net sales. EXXUA is anticipated to be a significant growth catalyst for Aytu, addressing unmet needs in the $22 billion US prescription MDD market. The product is distinguished by its novel mechanism and lack of sexual dysfunction side effects, positioning it as a transformative option for over 21 million Americans affected by MDD.

The most recent analyst rating on (AYTU) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Aytu BioScience stock, see the AYTU Stock Forecast page.

Aytu BioPharma Announces $12.9M Public Offering

On June 5, 2025, Aytu BioPharma announced an underwriting agreement with Lake Street Capital Markets for a public offering of common stock and prefunded warrants, aiming to raise approximately $12.9 million. The proceeds will be used for general corporate purposes and to commercialize EXXUA™ (gepirone) extended-release tablets. The offering, expected to close around June 9, 2025, is part of Aytu’s strategy to strengthen its market position in novel therapeutics for major depressive disorder.

The most recent analyst rating on (AYTU) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Aytu BioScience stock, see the AYTU Stock Forecast page.

Aytu BioScience Holds 2025 Annual Meeting

On May 21, 2025, Aytu BioScience held its 2025 Annual Meeting, where approximately 70% of the company’s common stockholders participated. During the meeting, all incumbent directors were reelected, an amendment to increase shares under the 2023 Equity Incentive Plan was approved, Grant Thornton LLP was ratified as the independent accounting firm, and executive compensation was endorsed through a non-binding advisory vote.

The most recent analyst rating on (AYTU) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Aytu BioScience stock, see the AYTU Stock Forecast page.